Calyxt, Inc. (CLXT): Price and Financial Metrics

Calyxt, Inc. (CLXT): $6.30

0.33 (+5.53%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add CLXT to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#328 of 471

in industry

CLXT Price/Volume Stats

Current price $6.30 52-week high $7.77
Prev. close $5.97 52-week low $1.25
Day low $6.01 Volume 254,600
Day high $7.77 Avg. volume 139,308
50-day MA $3.59 Dividend yield N/A
200-day MA $2.64 Market Cap 31.34M

CLXT Stock Price Chart Interactive Chart >


Calyxt, Inc. (CLXT) Company Bio


Calyxt, Inc., an agriculture biotechnology company, develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. The Company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. The company was founded in 2010 and is based in New Brighton, Minnesota


CLXT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLXT Latest Social Stream


Loading social stream, please wait...

View Full CLXT Social Stream

Latest CLXT News From Around the Web

Below are the latest news stories about CALYXT INC that investors may wish to consider to help them evaluate CLXT as an investment opportunity.

Calyxt Announces Stockholder Approval of Merger With Cibus

Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus.

Yahoo | May 19, 2023

Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

Yahoo | May 1, 2023

Calyxt Completes One-for-Ten Reverse Stock Split

Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022.

Yahoo | April 24, 2023

Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC.

Yahoo | April 18, 2023

Calyxt Announces Effective Date of Reverse Stock Split

Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022. Calyxt plans to file an amendment to its certificate of incorporation to effectuate the reverse stock split after the close of trading on April 24, 2023, and Calyxt's common stock, par value $0.0001 per share, will begin trading on an adjusted basis giving effect

Yahoo | April 7, 2023

Read More 'CLXT' Stories Here

CLXT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 75.00%
3-year -89.34%
5-year -96.42%
YTD N/A
2023 0.00%
2022 -93.08%
2021 -49.53%
2020 -39.80%
2019 -32.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!